Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 17/20 | 0.68 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12273794 | 0.91 | QPCT (0.70) | QPCTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12274129 | 0.89 | QPCT (0.67) | QPCTQPCTLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12273932 | 0.89 | QPCT (0.86) | QPCTQPCTLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12274128 | 0.88 | QPCT (0.66) | QPCTQPCTLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12274265 | 0.88 | QPCT (0.68) | QPCTQPCTLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12274427 | 0.88 | QPCT (0.68) | QPCTQPCTLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12273563 | 0.86 | QPCT (0.66) | QPCT | |
| SCHEMBL12274345 | 0.84 | QPCT (0.62) | QPCTQPCTL | |
| SCHEMBL12456230 | 0.82 | QPCT (0.52) | QPCTQPCTLKDM4E | |
| SCHEMBL12274403 | 0.82 | QPCT (0.61) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686313-B1 | BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2686313-A1 | BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8530670-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20120237475-A1 | Novel Inhibitors | PROBIODRUG AG (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123563-A1 | BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237475-A1 | Novel Inhibitors | GLS, NQO2, GLS2 | QPCT 5/4885QPCTL 13/4885MEN1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.